MAP Pharmaceuticals (NASDAQ:MAPP.DL)
CAPS Rating:
Pharmaceutical Preparations
Growing the love for investing
Pharmaceutical Preparations
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
MAP has no revenue and is losing large amounts of money each quarter (four in a row now). Before the recent financing deal it was worth less than $14 million on paper. Even now its worth less than $60 million, which doesn't support a $540 million market cap.